Novo Nordisk A/S (CPH:NOVO.B)
Denmark · Delayed Price · Currency is DKK | Market Cap | 1.45T |
| Revenue (ttm) | 315.60B |
| Net Income (ttm) | 103.77B |
| Shares Out | 4.44B |
| EPS (ttm) | 23.33 |
| PE Ratio | 13.94 |
| Forward PE | 13.73 |
| Dividend | 11.65 (3.58%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 3,775,851 |
| Average Volume | 6,549,466 |
| Open | 325.00 |
| Previous Close | 327.75 |
| Day's Range | 324.25 - 329.00 |
| 52-Week Range | 266.90 - 675.20 |
| Beta | 0.36 |
| RSI | 55.71 |
| Earnings Date | Feb 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial StatementsNews
Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market
The FDA approval of the Wegovy pill highlights many of the key themes Novo Nordisk will have to face in 2026.
Novo Nordisk (NVO) Secures Patent Victory in China for Semaglutide
Novo Nordisk (NVO) Secures Patent Victory in China for Semaglutide
Novo Nordisk A/S: China's Supreme People's Court delivers a positive ruling on the semaglutide compound patent
Today, the Supreme People's Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent
The End of Shots? 5 Biotech Stocks Rethinking Diabetes
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC , Dec. 31, 2025 /PRNewswire/ -- USA News Group News Commentary – Recent clinical trials achieving 83% insulin independence rates have ignited ...
Why Novo Nordisk Stock Dropped on Monday
The cost of Wegovy is about to decrease significantly in a populous overseas market.
Can Amgen's MariTide Take on Leaders in the Obesity Space?
AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.
Eli Lilly and Novo Nordisk Shares Dip After Cut Obesity Drug Prices in China
Eli Lilly and Novo Nordisk Shares Dip After Cut Obesity Drug Prices in China
Judge Halts US Drug Discount Overhaul, Blocks 340B Rebate Plan
A federal judge on Monday temporarily blocked the U.S. administration’s planned 340B Rebate Model Pilot Program, finding that regulators likely failed to meet basic administrative law requirements bef...
Novo Nordisk: A Sell As Oral Wegovy Pressures Margins
Eli Lilly (LLY) and Novo Nordisk (NVO) Slash GLP-1 Drug Prices in China
Eli Lilly (LLY) and Novo Nordisk (NVO) Slash GLP-1 Drug Prices in China
Novo Nordisk and Eli Lilly Slash Obesity Drug Prices in China
Novo Nordisk and Eli Lilly Slash Obesity Drug Prices in China
Wall Street Breakfast Podcast: Meta Snaps Up Manus
Meta (META) acquires Manus to bolster AI agent capabilities, advancing its focus on AI infrastructure and monetization beyond the metaverse. BA secures an $8.6B contract to deliver up to 50 F-15IA air...
Wegovy and Mounjaro Prices Slashed in China by Novo Nordisk and Eli Lilly
Wegovy and Mounjaro Prices Slashed in China by Novo Nordisk and Eli Lilly
Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient
The medicine developed by the100-year old Danish drugmaker may impact patients' brains in surprising ways
Novo Nordisk (NVO) Slashes Wegovy Prices in China Ahead of Patent Expiry
Novo Nordisk (NVO) Slashes Wegovy Prices in China Ahead of Patent Expiry
Novo Nordisk cuts Wegovy price in China
Eli Lilly (LLY) and Novo Nordisk (NVO) May Benefit from New Medicare Model
Eli Lilly (LLY) and Novo Nordisk (NVO) May Benefit from New Medicare Model
Novo Nordisk Halves Wegovy Prices In China Ahead Of Generic Threat
Novo Nordisk A/S (NYSE: NVO) has reportedly slashed list prices for its obesity drug Wegovy by about 50% in parts of China, signaling a defensive move ahead of rising generic competition. Citing loca...
Novo Nordisk Cuts Wegovy Prices in China Ahead of Patent Expiration
Novo Nordisk Cuts Wegovy Prices in China Ahead of Patent Expiration
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
This Beaten-Down Stock Just Jumped By 8%. Time to Buy?
Pharmaceutical giant Novo Nordisk just earned approval for an oral version of Wegovy. This could help improve its position in the increasingly competitive weight loss market.
Novo cuts Wegovy prices in some Chinese provinces, local media reports
Danish drugmaker Novo Nordisk has nearly halved prices of its obesity drug Wegovy in some Chinese provinces, local media Yicai reported on Monday.
Novo Nordisk (NVO) Reduces Wegovy Prices in China Amid Competition Concerns
Novo Nordisk (NVO) Reduces Wegovy Prices in China Amid Competition Concerns
Novo Nordisk Cuts Wegovy Prices in China Ahead of Generic Threat
Novo Nordisk Cuts Wegovy Prices in China Ahead of Generic Threat
The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA.
Novo Nordisk's CagriSema could be a brand new growth driver for the company. Eli Lilly's orforglipron is breaking into a new, lucrative market.